|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Operation and formation costs | ||||
| Research and development services | ||||
| Research and development services | ||||
| Collaboration revenue | ||||
| Royalty | ||||
| Total research and development services | ||||
| Operating expenses: | ||||
| Research and development | ||||
| General and administrative | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Other (expense) income: | ||||
| Interest income – bank | ||||
| Interest earned on Cash and marketable securities held in Trust Account | ||||
| Penalties and interest on taxes | ||||
| Unrealized loss on marketable securities held in Trust Account | ||||
| Derecognition of Mabwell liability (see Note 19) | ||||
| Gain on reversal of excise taxes payable (see Note 10) | ||||
| Other income (see Note 2) | ||||
| Change in fair value of forward purchase agreement asset | ||||
| Change in fair value of SEPA put rights asset | ||||
| Change in fair value of embedded derivative liability | ||||
| Gain on extinguishment of accrued liabilities | ||||
| Loss on settlement of convertible notes | ||||
| Interest income | ||||
| Interest expense | ||||
| Total other income, net | ||||
| Income before provision for income taxes | ||||
| Provision for income taxes | ||||
| Net income | ||||
| Redeemable common stock | ||||
| Nonredeemable common stock | ||||
| Total net income | ||||
| Net loss | ||||
| Deemed dividend resulting from the warrant down round | ||||
| Net loss attributable to common stockholders | ||||
| Loss per share | ||||
| Basic (in Dollars per share) | ||||
| Series A common stock | ||||
| Series B common stock | ||||
| Redeemable common stock | ||||
| Nonredeemable common stock | ||||
| Total basic (in Dollars per share) | ||||
| Diluted (in Dollars per share) | ||||
| Series A common stock | ||||
| Series B common stock | ||||
| Redeemable common stock | ||||
| Nonredeemable common stock | ||||
| Total diluted (in Dollars per share) | ||||
| Weighted average shares outstanding - basic (in Shares) | ||||
| Redeemable common stock | ||||
| Nonredeemable common stock | ||||
| Total weighted average shares outstanding - basic (in Shares) | ||||
| Weighted average shares outstanding - diluted (in Shares) | ||||
| Redeemable common stock | ||||
| Nonredeemable common stock | ||||
| Total weighted average shares outstanding - diluted (in Shares) | ||||
Loading...